LY3361237 + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Lupus Erythematosus, Systemic
Conditions
Lupus Erythematosus, Systemic
Trial Timeline
May 21, 2019 → Feb 15, 2021
NCT ID
NCT03933943About LY3361237 + Placebo
LY3361237 + Placebo is a phase 1 stage product being developed by Eli Lilly for Lupus Erythematosus, Systemic. The current trial status is completed. This product is registered under clinical trial identifier NCT03933943. Target conditions include Lupus Erythematosus, Systemic.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05123586 | Phase 2 | Terminated |
| NCT04975295 | Phase 1 | Completed |
| NCT03933943 | Phase 1 | Completed |
Competing Products
20 competing products in Lupus Erythematosus, Systemic